I read with interest the paper of Henderson et al. I which describes assays for homovanillic acid (HV A), hydroxymethylmandelic acid (HMMA) and dopamine, and reports age-related reference ranges for these metabolites. Estimation of the urinary excretion of these metabolites has been a major factor in the diagnosis of neuroblastoma in children since the first report in 1957 of such an association.? Indeed, several studies have been, and are being, conducted to assess the feasibility and effectiveness of screening for neuroblastoma using these metabolites as tumour markers.I? It is therefore a vital area of research that Dr Henderson and his colleagues address and, in particular, the determination of accurate reference ranges for the three metabolites is of paramount importance if the diagnostic procedure is to be effective. Figure 3 of their paperI clearly shows the relationship between the creatinine adjusted levels of HVA, HMMA and dopamine and age. Also shown are the 'approximate upper reference limits' determined by simply drawing a curve across the uppermost data points. Henderson et al. comment that there is no simple way of determining an upper limit since the data do not have a Gaussian distribution for any given age. On the contrary. there are several. A simple Box-Cox transformation," of which the logarithmic transformation is a special case, might well produce data with a Gaussian distribution. The usual regression procedures or more sophisticated procedures? may then be used to determine upper limits for the transformed data which are then back transformed to give the required upper limits. After transformation, if the data are still not distributed in a Gaussian fashion alternative nonparametric techniques may be employed; the procedure of Healy et al. 8 is useful in this case (see Cole et al:? for an application in a neuroblastoma screening context).
The technique used by Henderson et al. has the flaw that it is implicitly linked to the sample size.' If for example 280 children rather than 140 children had been assessed the upper limit would be expected to increase; if 70 children were assessed a lower value would be expected. If the Ann Clin Biochem 1993; 30: 499-518 techniques discussed above are employed this does not occur. Upper limits determined using these procedures will have a known proportion of children below such a limit. If levels of HV A, HMMA and dopamine are to be used as part of a screening procedure for neuroblastoma then the specificity of the test would be known and could be fixed at any desired level (usually 950/0 or 99%). If an upper limit is simply drawn across the uppermost data points the specificity of the test is not known and will depend upon the sample size used to determine the limit. Finally, the authors claim that their procedure would minimize the number of false positives; this is not true as classifying all individuals as test negative would achieve this. 
Author's reply
My colleagues and I thank Mr Cole for his comments but think that he has misunderstood the purpose of our paper. We would agree that accurate and precisely defined reference ranges would be necessary for any proposed screening programme. However, our data was not intended for that purpose. We collected samples from sick children in whom neuroblastoma had been excluded. This is an appropriate control group for a diagnostic test. For the purposes of screening, the reference data would need to be collected from healthy, asymptomatic children, all of the same age. We did not report age-related reference ranges. We took care to point out that this was age-related reference data. As we stated in our paper the major clinical users of our assays are provided with copies of the graphs and so can judge the significance of any clinical results against this data. In order to employ the statistical methods suggested by Mr Cole, the data would first need to be subdivided into small age bands; otherwise the pattern of change would be lost. There would then be insufficient data in each group for any analysis to be useful. The lines drawn across the tops of the data sets were a pragmatic attempt to delineate a boundary to the data. We fully realize the limitations of this approach and felt that this had been made clear in the discussion.
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Index of individuality and utility of population based reference range
Dot et at. calculated the index of individuality of prothrombin time (PT) and activated partial thromboplastin time (APTT) as 0'96 and 0'68, respectively, and concluded that PT and APTT may not be appropriate for diagnosis using population based reference values.' They rightly pointed out that within subject changes of these quantities could be masked by between subject Ann Clin Biochem 1993, 30 variation and quoted two clinical studies which showed that the clinical performance of these quantities was pOOr. 2 ,3 Two points need to be clarified. First, it is misleading to conclude that the use of population based reference intervals for a quantity is inappropriate on the basis of an < 1·4 index of individuality. Harris who introduced the concept of the index of individuality showed that the population based reference range of a quantity with a low index of individuality was not sensitive in detecting (statistically) significant but small changes in individual patients." But by the same token, these tests would have high diagnostic specificity, i.e. when an individual measurement exceeds the reference range it is likely to be highly significant for that individual. Interestingly most analytes used in routine clinical laboratories have low indices of individuality. 4 Conversely, in the case of a quantity with a high index of individuality (~1'4), though the reference range is sensitive in detecting small but statistically significant changes in an individual, it lacks diagnostic specificity. The 95010 intervals of an individual with above average biological variation would exceed the population based reference range. So would the 95010 intervals of an individual with average variation whose mean value does not lie close to the mean of the population. This point has been reiterated more recently in the context of creatinine measurements.'
Secondly, this study brings out clearly the difference between statistical significance and clinical significance. The low index of individuality of PT and APTT (by implication lack of diagnostic sensitivity) is given as the reason for the lack of utility of the reference range for diagnostic purposes. But the clinical studies quoted as confirming this in fact show that an important reason for the poor performance of these tests is their lack of diagnostic specificity. This certainly could not have been predicted by the low index of individuality. In addition, it can be easily inferred that, contrary to Dot et at. 's suggestion, longitudinal comparison of PT and APTT in a normal individual would also lack diagnostic specificity, if one were to use 95010 confidence intervals for that individual. This dichotomy between statistical significance and clinical relevance reiterates the need to use reference ranges statistically derived from the normal population with caution, and makes a strong case for determining clinically relevant cut-off points. Clinicians often use clinically relevant decision
